Slide 1: Ovation 2, Trial Results in Advanced Ovarian Cancer Patients
IMUNON Ovation 2, Trial Results in Advanced Ovarian Cancer Patients Protocol Planned, Phase 2 Data Readout July 30, 2024 8k Filing “SIMUNON | © 2024 IMUNON, Inc pace | 1
Slide 2: Safe Harbor Statement
Safe Harbor Statement Disclosures For the purposes of this notice, the “presentation” that follows shall mean and include the slides that follow, the oral presentation of the slides by members of management of Imunon, Inc, (‘IMUNON” or the “Company”) or any person on their behalf, any question-and-a
Slide 3: IMNN-001 and Ovarian Cancer Context
IMNN-001 and Ovarian Cancer Context “SIMUNON | © 2024 IMUNON, inc pace | 3
Slide 4: IMNN-001 could reset the standard of care for women with ovarian cancer: Reasons to believe
IMNN-001 could reset the standard of care for women with ovarian cancer: Reasons to believe IMNN-001 allows durable therapeutic and dose-dependent production and release of IL-12 in the Tumor Micro-Environment [1] * Benefits of IMNN-001 therapy are supported by known long-lived actions of IL-12 recr
Slide 5: The OS benefits of IMNN-001 therapy are supported by known long-lived actions of IL-12
The OS benefits of IMNN-001 therapy are supported by known long- lived actions of IL-12 on the immune system * IL-12 promotes activation, proliferation and persistence of cytotoxic T-cells of both innate and adaptive immune system. * Innate immune system- cytotoxic natural killer T-cells or NKT cell
Slide 6: Potent Immune Mechanisms and Clinical Efficacy Supports Strong R&D Interest in IL-12
Potent Immune Mechanisms and Clinical Efficacy Supports Strong R&D Interest in IL-12: Current Strategies to Minimize Serious Systemic Toxicity * Complete or partial responses to rlL-12 have been observed in: * Melanoma! Renal carcinoma! AIDS-related Kaposi sarcoma? Non-Hodgkin's lymphoma’ * However,
Slide 7: IMNN-001 has Advantages over other Approaches to IL-12 Delivery
IMNN-001 has Advantages over other Approaches to IL-12 Delivery Comparison with rlL-12 * Physiological profile of IL-12 with durable local increases compared to rapid high systemic increases accompanying serious systemic toxicity following rlL-12. * Local increases in IL-12 by IMNN-O01will be safer
Slide 8: OVATION-1 Study in Neoadjuvant Ovarian Cancer
OVATION-1 Study in Neoadjuvant Ovarian Cancer Dose Dependent Biological (IL-12 & IFN-y) and Clinical Responses Demonstrate POC Radiographic Total) | Cohort! ] Cohort2 | Coho] Cohort Response. 36 mg/m? 47 mg/m? _| 61 mg/m? _| 79 mg/m? R 2 H 0 0 1 Tumor Response [PR 10 0 3 3 + SD z 2 0 0 0 ‘Objective
Slide 9: IMNN-001: OVATION Ovarian Cancer Study
IMNN-001: OVATION 2 Ovarian Cancer Study To Determine Efficacy and Biological Activity With NACT in Stage III/IV Patients mization 1 Arm to < IATION 2 Q Adivvant Chemotherapy Newly Diagnosed Neoadjuvant Chemotherapy (NACT) Interval Debulking (Maintenance Therapy) Ovarian Cancer + Surgery + Tissue Co
Slide 10: With OVATION2, IMUNON Targets a Large Patient Population with High Unmet Needs
With OVATION2, IMUNON Targets a Large Patient Population with High Unmet Needs 60% of newly diagnosed advanced OC patients and no new treatment in decades * According to ovarian cancer experts, over 60% of patients are in need for a neoadjuvant treatment ahead of debulking surgery, representing appr
Slide 11: Current Standard of Care Established years ago
Current Standard of Care Established 25 years ago Overview of Pivotal Trials Defining NACT SOC In patients with stage IIIC/IV ovarian cancer, neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) demonstrated non-inferior overall survival (OS) to primary debulking surgery (PDS
Slide 12: Adding Phase 2 trial to Clinical Development Strategy in Ovarian Cancer
Adding Phase 2 trial to Clinical Development Strategy in Ovarian Cancer Effectively Reduces Risk Phase 2 trial intended to generate additional clinical data and gain confidence in the clinical effect prior to Phase 3 Given interest in Overall Survival, and Progression Free Survival, Phase 2 that are
Slide 13: Overall Survival Consistently Shows Greater Protective Effects with Immunotherapies than PFS
Overall Survival Consistently Shows Greater Protective Effects with Immunotherapies than Progression Free Survival [Ei Overall survival HH Progression-free survival i A :| | : J I I a Fertis,2016 Borghael, 2015 Brahmer, 2015 Motzer, 2015 Carbone, 2017 Bellmunt, 2017 Herbst, 2016 Ribas, 2015 Weber, 2
Slide 14: Overall Survival Consistently Shows Greater Protective Effects with Immunotherapies than PFS
Overall Survival Consistently Shows Greater Protective Effects with Immunotherapies than Progression Free Survival Meta Analysis from systematic search covering 10 studies, 4,653 patients spanning 8 clinical settings supports importance of OS | Table2. Efficacy Data g 5 os f PD-1Group, Control Group
Slide 15: As OVATION-2 OS Data Mature, the Level of Evidence for a Robust Benefit Increases
As OVATION-2 OS Data Mature, the Level of Evidence for a Robust Benefit Increases Hazard Ratio dropped from 0.86 to 0.74, difference in Median OS increased to 11 months Overall Survival Parameters September 2023 Interim Analysis | June 2024 Analysis Number of Events 37 Ao Improvement in Survival (mo
Slide 16: $1.6B to $2.1B Market Opportunity in Patients Newly Diagnosed with Advanced Stage Ovarian Cancer
$1.6B to $2.1B Market Opportunity in Patients Newly Diagnosed with Advanced Stage Ovarian Cancer Worldwide diagnoses, yearly: 300,000" US diagnoses each year: 20,0007 Population Assumptions, US market: ~9.5k patients treated with IMNN-001 — 80% are Newly diagnosed — 60% of market captured Price Assu
Slide 17: Ovation 2, Trial Results in Advanced Ovarian Cancer Patients
Ovation 2, Trial Results in Advanced Ovarian Cancer Patients Protocol Planned, Phase 2 Data Readout “SIMUNON | © 2024 IMUNON, inc pace | 17
Slide 18: Summary: Ovation Advanced Ovarian Cancer Patients Trial Results
Summary: Ovation 2 Advanced Ovarian Cancer Patients Trial Results If results are replicated in phase 3, we believe that IMNN-001 will be an approved 1* line treatment for Ovarian Cancer that will change the Standard of Care An 11-month improvement in Overall Survival by IMNN-001 in intent-to-treat (
Slide 19: Clinical Advisory Committee Summary
Clinical Advisory Committee Summary Patients who received IMNN-001 in the trial lived longer than those in the control arm * If they received a PARP inhibitor or if they had at least 20% of treatment in the protocol they did even better These Phase 2 results are promising and if confirmed in an adeq
Slide 20: Ovation 2: Protocol Planned Phase Data Readout
Ovation 2: Protocol Planned Phase 2 Data Readout Advanced Ovarian Cancer Patients Median time to event, Experimental vs Control Hazard Ratio, Experimental vs Control (months) Overall Survival ITT n=112 40.5 vs 29.4 0.74 (0.42; 1.30) pNS (secondary 220% of protocol-specified 45.1 vs 29.4 0.64 (0.35;